CTI Biopharma Corp is a biopharmaceutical company focused on the development and commercialization of less toxic, more effective cancer therapies. The company's therapeutic area is blood-related cancers. One of the company's products, Pixantrone (PIXUVRI), received conditional marketing approval in the EU in 2012 to treat refractory aggressive B-cell non-Hodgkin lymphoma. Another product is Pacritinib, an oral tyrosine kinase inhibitor to treat mutations such as Janus associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).